Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study

Dyslipidemia (DL) is commonly associated with non‐alcoholic fatty liver disease (NAFLD). Pemafibrate, a selective peroxisome proliferator activated receptor α modulator (SPPARMα), has been shown to improve liver function among patients with DL. The aim of this single‐arm prospective study is to evaluate the efficacy of pemafibrate in NAFLD patients with DL.

[1]  H. Aburatani,et al.  Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content , 2020, Scientific Reports.

[2]  W. Marlicz,et al.  Changes of the Fatty Acid Profile in Erythrocyte Membranes of Patients following 6-Month Dietary Intervention Aimed at the Regression of Nonalcoholic Fatty Liver Disease (NAFLD) , 2018, Canadian journal of gastroenterology & hepatology.

[3]  F. Violi,et al.  Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease , 2018, Journal of clinical medicine.

[4]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[5]  S. Yamashita,et al.  Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. , 2017, Journal of clinical lipidology.

[6]  C. Bonfiglio,et al.  Significant decrease of saturation index in erythrocytes membrane from subjects with non-alcoholic fatty liver disease (NAFLD) , 2017, Lipids in Health and Disease.

[7]  P. Calder,et al.  Erratum: Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study , 2017, European Journal of Clinical Nutrition.

[8]  H. Shimano,et al.  Selective peroxisome proliferator‐activated receptor‐α modulator K‐877 efficiently activates the peroxisome proliferator‐activated receptor‐α pathway and improves lipid metabolism in mice , 2017, Journal of diabetes investigation.

[9]  A. Nakajima,et al.  Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis , 2017, Scientific Reports.

[10]  Yuquan Wei,et al.  FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy , 2016, Molecular and Cellular Biochemistry.

[11]  M. Moriguchi,et al.  Serum alanine aminotransferase predicts the histological course of non‐alcoholic steatohepatitis in Japanese patients , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[12]  M. Honda,et al.  Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[13]  T. Saibara,et al.  Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients , 2014, Journal of Gastroenterology.

[14]  B. Neuschwander‐Tetri,et al.  Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis , 2013, Alimentary pharmacology & therapeutics.

[15]  F. Foufelle,et al.  Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c , 2010, Diabetes, obesity & metabolism.

[16]  G. Gores,et al.  Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. , 2010, Journal of hepatology.

[17]  P. Calder.  Omega-3 Fatty Acids and Inflammatory Processes , 2010, Nutrients.

[18]  S. Klein,et al.  Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications , 2010, Hepatology.

[19]  Michelle M Wiest,et al.  The plasma lipidomic signature of nonalcoholic steatohepatitis , 2009, Hepatology.

[20]  Shuiping Zhao,et al.  Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up‐regulating peroxisome proliferator‐activated receptor‐α , 2009, British journal of pharmacology.

[21]  Hirokazu Takahashi,et al.  Dysfunctional very‐low‐density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis , 2009, Hepatology.

[22]  S. Caldwell,et al.  Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[23]  J. Fruchart.  Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. , 2009, Atherosclerosis.

[24]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  T. Saibara,et al.  What are the risk factors and settings for non‐alcoholic fatty liver disease in Asia–Pacific? , 2007, Journal of gastroenterology and hepatology.

[26]  Philippe Lefebvre,et al.  Sorting out the roles of PPARα in energy metabolism and vascular homeostasis , 2006 .

[27]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[28]  Jean Girard,et al.  Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. , 2005, The Journal of clinical investigation.

[29]  H. Sampath,et al.  Polyunsaturated fatty acid regulation of genes of lipid metabolism. , 2005, Annual review of nutrition.

[30]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[31]  X. Prieur,et al.  The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element* , 2003, Journal of Biological Chemistry.

[32]  M. Saad,et al.  Peroxisome Proliferator-activated Receptor α (PPARα) Influences Substrate Utilization for Hepatic Glucose Production* , 2002, The Journal of Biological Chemistry.

[33]  F. Berrino,et al.  Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. , 2001, Journal of the National Cancer Institute.

[34]  J. Ntambi.  Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. , 1999, Journal of lipid research.

[35]  M. Landray,et al.  Lipid-lowering drugs and homocysteine , 1999, The Lancet.

[36]  J. Auwerx,et al.  Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators* , 1997, The Journal of Biological Chemistry.

[37]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[38]  J. Auwerx,et al.  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.

[39]  B. Staels,et al.  Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. , 2006, The Journal of clinical investigation.

[40]  M. Saad,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production. , 2002, The Journal of biological chemistry.